Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Prepaid Assets (2016 - 2025)

Karyopharm Therapeutics' Prepaid Assets history spans 14 years, with the latest figure at $9.2 million for Q4 2025.

  • For Q4 2025, Prepaid Assets fell 24.98% year-over-year to $9.2 million; the TTM value through Dec 2025 reached $9.2 million, down 24.98%, while the annual FY2025 figure was $9.2 million, 24.98% down from the prior year.
  • Prepaid Assets reached $9.2 million in Q4 2025 per KPTI's latest filing, up from $8.0 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $31.5 million in Q3 2022 to a low of $8.0 million in Q3 2025.
  • Average Prepaid Assets over 5 years is $14.9 million, with a median of $13.7 million recorded in 2021.
  • Peak YoY movement for Prepaid Assets: skyrocketed 210.81% in 2022, then crashed 57.63% in 2023.
  • A 5-year view of Prepaid Assets shows it stood at $14.0 million in 2021, then soared by 41.19% to $19.8 million in 2022, then tumbled by 40.4% to $11.8 million in 2023, then increased by 3.66% to $12.2 million in 2024, then fell by 24.98% to $9.2 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Prepaid Assets are $9.2 million (Q4 2025), $8.0 million (Q3 2025), and $8.2 million (Q2 2025).